Pfizer Ventures participated in a series A round for genetic therapeutics developer Anjarium Biosciences that was co-led by Abingworth and Gimv.

Switzerland-based gene therapy developer Anjarium Biosciences has completed a CHF55.5m ($60m) series A round that included Pfizer Ventures, the strategic investment arm of pharmaceutical firm Pfizer.

Investment firms Abingworth and Gimv co-led the round, which also featured private equity firm Omega Funds and Surveyor Capital, a subsidiary of hedge fund manager Citadel.

Anjarium is developing non-viral tissue-targeted gene therapies to treat genetic diseases. It intends to channel the funding into platform development, increasing its staff numbers and advancing its product…

Robert Lavine

Robert Lavine is special features editor for Global Venturing.